(1S)-1,5-脱氢-1-C-[3-[[5-(4-氟苯基)-2-噻吩基]甲基]-4-甲基苯基]-D-葡萄糖醇

溶解度:Unknown

储存条件:at -20℃ 2 years

生物活性

Canagliflozin is an experimental drug being developed by Johnson & Johnson for the treatment of type 2 diabetes.^[1][2] It is an inhibitor of subtype 2 sodium-glucose transport protein (SGLT2), which is responsible for at least 90% of the glucose reabsorption in the kidney. Blocking this transporter causes blood glucose to be eliminated through the urine.^[3]

参考文献

1. ^ New J&J diabetes drug effective in mid-stage study, Jun 26, 2010
2. ^ Edward C. Chao (2011). "Canagliflozin". Drugs of the Future 36 (5): 351-357. doi:10.1358/dof.2011.36.5.1590789. 
3. ^ Prous Science: Molecule of the Month November 2007